News Category
GeoVax's next-generation MVA-X vaccine provides durable single-dose protection against lethal Clade I mpox and other orthopoxviruses, potentially simp...
Onco-Innovations is integrating manufacturing, preclinical, and regulatory efforts to advance its PNKP-targeting cancer therapy ONC010 toward first-in...
Patients with small cell lung cancer should ask about clinical trials at their first appointment, as emerging treatments offer new hope and improved q...
Telomir Pharmaceuticals announced that its lead drug candidate Telomir-Zn inhibited growth in human and canine osteosarcoma cell lines at similar low ...
Dr. Wael Sakr has announced a one-time $1,000 scholarship for undergraduate pre-med students, aiming to support the next generation of physicians and ...
Creative Biolabs has expanded its single-cell multi-omics and RNA sequencing solutions, offering integrated services that enable high-resolution cellu...
A comprehensive review reveals that the tumor microenvironment actively reshapes natural killer cells into distinct functional subsets, offering new t...
The September 17 Life Sciences Virtual Investor Forum will connect investors with seven companies developing therapies for cancer, fibrosis, antibioti...
VERAXA Biotech's appointment of Dr. Christoph Erkel as chief scientific officer signals a strategic push to advance its BiTAC® T-cell engager and othe...
Quantum BioPharma's Lucid-MS, a first-in-class non-covalent PAD2 inhibitor, is moving toward a Phase 2 trial in multiple sclerosis following FDA clear...
Onco-Innovations' CMO detailed the company's novel PNKP-targeting cancer drug ONC010, which uses synthetic lethality and nanoparticle delivery to pote...
Quantum BioPharma's FDA clearance to proceed with a Phase 2 trial of Lucid-MS marks a significant step for a first-in-class multiple sclerosis therapy...
Kairos Pharma's CEO will present at a major investment conference, underscoring the company's progress in developing ENV-105 to overcome cancer drug r...
GeoVax supports the new global mpox vaccine stockpile, highlighting its GEO-MVA candidate's readiness to contribute to sustainable and equitable vacci...
VERAXA Biotech's appointment of Raju Willener as CFO brings extensive financial leadership to support its capital strategy and oncology pipeline devel...
Onco-Innovations Ltd. strengthens its clinical foundation for its lead candidate ONC010, a nanoparticle-encapsulated PNKP inhibitor, through manufactu...
OS Animal Health, a subsidiary of OS Therapies, presented its lead candidate OST-HER2 for canine osteosarcoma at the Disruptive Growth & Life Sciences...
Quantum BioPharma's FDA clearance to test Lucid-MS in a Phase 2 trial marks a pivotal step toward the first therapy that may repair myelin in MS patie...
Researchers at Washington University School of Medicine have advanced laser interstitial thermal therapy (LITT) as a less invasive brain cancer treatm...
Quantum BioPharma's FDA clearance to test Lucid-MS, a first-in-class remyelinating agent, in a Phase 2 trial for MS marks a potential breakthrough in ...
NanoViricides has registered its Phase II trial for NV-387 Oral Gummies against Ebola in the DRC, marking a critical step in developing an oral antivi...
Quantum BioPharma's FDA clearance for a Phase 2 trial of Lucid-MS, a first-in-class remyelination agent, marks a pivotal step toward a new approach fo...
The FDA's approval of ZYN nicotine pouches with modified risk claims offers adult smokers a scientifically validated alternative to cigarettes, while ...
A large study reveals that the timing of brain metastasis development significantly impacts survival in colorectal cancer patients, underscoring the n...
Onco-Innovations' ONC010, a PNKP inhibitor for cancer, has achieved high-purity API production and is progressing toward a First-in-Human study in Aus...
VERAXA Biotech's appointment of seasoned financial executive Raju Willener as CFO signals a strategic move to bolster its capital markets expertise an...
OS Therapies' participation in the Moody Capital conference underscores a pivotal period as it awaits key regulatory decisions and survival data for i...
A Swiss preclinical study suggests that administering immunotherapy prior to surgical removal of glioblastoma tumors significantly improves treatment ...
New Mass General Brigham research links unintended thymus radiation during lung cancer treatment to worse outcomes, suggesting that protecting this im...
Dr. Salman Fazal, a hematologist and stem cell transplant expert at UPMC Hillman Cancer Center, has been recognized as a Castle Connolly Top Doctor fo...
NanoViricides is progressing its measles treatment NV-387 toward Phase II clinical trials, a critical step given the resurgence of measles cases and t...
TransCode Therapeutics announced that its lead candidate TTX-MC138 demonstrated significant survival benefits in a preclinical model of breast cancer ...
A nurse's personal battle with metastatic triple-negative breast cancer underscores the critical need for early access to innovative treatments like a...
A new educational campaign highlights the importance of PSMA testing in prostate cancer care, emphasizing its role in guiding treatment decisions and ...
The NMPA approval allows Heidelberg Pharma and Huadong Medicine to initiate a Phase Ib/II trial of HDP-101 in combination with standard regimens for r...
New peer-reviewed research demonstrates that VolitionRx's Nu.Q NETs H3.1 biomarker independently predicts 28-day mortality and renal replacement thera...
Novogenia's U.S. launch of the MGT Plus methylation test, which analyzes 27 genes across six pathways, marks a significant expansion in personalized g...
Citius Pharmaceuticals has transitioned to a commercial-stage biopharma with its FDA-approved LYMPHIR generating early revenue, while its late-stage p...
Annovis Bio's corporate update webinar will highlight its Phase 3 Alzheimer's trial data expectations and expanded Parkinson's development, underscori...
A new preprint study demonstrates that a personalized mRNA vaccine derived from a patient's tumor can prevent melanoma recurrence for years, highlight...
An upcoming webinar by Creative Biolabs will discuss modeling T cell dysfunction in the tumor microenvironment, highlighting the importance of metabol...
Dr. David Zelby, a Marietta prosthodontist with over 40 years of experience, has been named a 2026 Castle Connolly Top Dentist, an honor given to only...
A novel T cell therapy shows promise in treating recurrent glioblastoma, a condition with limited options, potentially transforming care for patients.
The collaboration between VERAXA Biotech and Secarna Pharmaceuticals shows promising early in vitro results for a novel antibody oligonucleotide conju...
VERAXA Biotech has moved its VXA-222 bispecific antibody-drug conjugate into preclinical development, signaling progress in its oncology pipeline and ...
The Keith Dagostino Scholarship for Cancer Survivors opens applications for undergraduate students who have overcome cancer, offering financial aid an...
VERAXA Biotech's favorable Scientific Advice from Germany's Paul-Ehrlich-Institute de-risks the clinical development of its lead BiTAC-TCE therapy, po...
VERAXA Biotech's proprietary BiTAC platform, which uses dual-targeting 'AND-gated' architecture, is progressing through pipeline milestones including ...
